202220212020201920182017201620152014 January 19, 2022 Summary ToggleSpero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients January 04, 2022 Summary ToggleSpero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720 January 03, 2022 Summary ToggleSpero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
